
Eli Lilly & Co. said it has suspended investment, promotional activity and new clinical trials in Russia, and has stopped exporting nonessential medicines to the country, in response to the war in Ukraine.
The Indianapolis-based drugmaker, which is one of the world’s biggest producers of insulin, said in an emailed statement that it will continue to deliver cancer and diabetes medicines to patients in Russia.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app